Kinnate Biopharma Inc. (KNTE) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in San Francisco, CA, United States. The current CEO is Nima Farzan.
KNTE has IPO date of 2020-12-03, 84 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $124.99M.
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
